Table 3.
Toxicities (>1.0%) attributed to therapy in assessable patients (n = 298 courses)
| Adverse event | All, n (%) | Grade 3/4, n (%) |
|---|---|---|
| Leukopenia | 209 (70.1) | 85 (28.5) |
| Anemia | 160 (53.7) | 26 (8.7) |
| Neutropenia | 152 (51.0) | 73 (24.5) |
| Hypokalemia | 79 (26.5) | 1 (0.3) |
| Hyponatremia | 79 (26.5) | 0 (0.0) |
| ALT increased | 75 (25.2) | 0 (0.0) |
| Diarrhea | 62 (20.8) | 11 (3.7) |
| Hypoalbuminemia | 61 (20.5) | 0 (0.0) |
| Hypertriglyceridemia | 51 (17.1) | 0 (0.0) |
| Hyperbilirubinemia | 40 (13.4) | 0 (0.0) |
| AST increased | 38 (12.8) | 0 (0.0) |
| Proteinuria | 32 (10.7) | 0 (0.0) |
| Hypothyroidism | 25 (8.4) | 0 (0.0) |
| Thrombocytopenia | 15 (5.0) | 2 (0.7) |
| Fatigue | 14 (4.7) | 4 (1.3) |
| Dyspepsia | 13 (4.4) | 0 (0.0) |
| Myalgia | 11 (3.7) | 0 (0.0) |
| Anorexia | 10 (3.4) | 2 (0.7) |
| Weight loss | 10 (3.4) | 2 (0.7) |
| Abdominal pain | 9 (3.0) | 3 (1.0) |
| Hypertension | 8 (2.7) | 2 (0.7) |
| DIC | 6 (2.0) | 0 (0.0) |
| Fever | 6 (2.0) | 1 (0.3) |
| Skin ulceration | 6 (2.0) | 3 (1.0) |
| Bone pain | 6 (2.0) | 0 (0.0) |
| Epistaxis | 5 (1.7) | 0 (0.0) |
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; DIC, disseminated intravascular coagulation.